Pune: Emcure Pharmaceuticals Q2FY26 results showcased a strong performance across domestic and international markets, with consolidated revenue from operations reaching ₹2,270 crore, up 13.4% year-on-year (YoY).
The company’s Profit After Tax (PAT) surged 24.7% YoY to ₹251 crore, reflecting operational efficiency and strong business momentum.
Emcure Pharmaceuticals Q2FY26: Steady Growth Across Segments
Emcure Pharmaceuticals Q2FY26 financials revealed an EBITDA of ₹439 crore, growing 15.2% YoY, with EBITDA margins improving to 19.3%.
The domestic business contributed ₹1,031 crore, up 10.6% YoY, driven by the strong performance of key therapies and new product initiatives.
Also Read: Novo Nordisk India Partners with Emcure Pharma to Launch Poviztra for Weight Management
International sales reached ₹1,238 crore, marking a 15.8% YoY growth. The European market led with a 23% increase, aided by new product launches and manufacturing scale-up at Manx. Canada also delivered an 18% rise, while the Rest of the World segment continued to maintain steady growth led by non-ARV products.
Strategic Partnerships and Expansions Boost Q2 Performance
During the quarter, Emcure strengthened its domestic market position through strategic moves, including a partnership with Novo Nordisk to launch Poviztra – a biological injectable semaglutide used for chronic weight management and cardiovascular risk reduction.
Emcure will serve as the exclusive distributor for Poviztra in India. The company also completed the acquisition of the minority stake in its subsidiary, Zuventus.
Commenting on the results, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said, “Q2 witnessed robust performance across all business segments. Our Novo Nordisk partnership provides us an early entry into the fast-growing obesity segment. We remain focused on delivering growth along with margin enhancement in all our key markets.”
Also Read: Tenthpin Launches Center for Life Sciences Cloud Solutions in Pune
Emcure Pharmaceuticals Q2FY26: Financial Highlights
- Revenue from operations: ₹2,270 crore, up 13.4% YoY
- EBITDA: ₹439 crore, up 15.2% YoY, margins at 19.3%
- PAT: ₹251 crore, up 24.7% YoY
- Domestic sales: ₹1,031 crore, up 10.6% YoY
- International sales: ₹1,238 crore, up 15.8% YoY
- Europe: +23%
- Canada: +18%
- Emerging Markets: +8.6%
Emcure Pharmaceuticals, headquartered in Pune, continues to build on its diversified therapeutic portfolio and global footprint across 70+ countries, including Europe and Canada.
